Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Clearside Biomedical, Inc is a biotechnology business based in the US. Clearside Biomedical shares (CLSD) are listed on the NASDAQ and all prices are listed in US Dollars. Clearside Biomedical employs 33 staff and has a trailing 12-month revenue of around USD$9.8 million.
|52-week range||USD$1.1 - USD$4.53|
|50-day moving average||USD$3.6634|
|200-day moving average||USD$2.195|
|Wall St. target price||USD$6.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.962|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$9.8 million|
|Gross profit TTM||USD$2.2 million|
|Return on assets TTM||-39.97%|
|Return on equity TTM||-158.74%|
|Market capitalisation||USD$200.1 million|
TTM: trailing 12 months
There are currently 399,369 Clearside Biomedical shares held short by investors – that's known as Clearside Biomedical's "short interest". This figure is 37.9% down from 643,624 last month.
There are a few different ways that this level of interest in shorting Clearside Biomedical shares can be evaluated.
Clearside Biomedical's "short interest ratio" (SIR) is the quantity of Clearside Biomedical shares currently shorted divided by the average quantity of Clearside Biomedical shares traded daily (recently around 1.5 million). Clearside Biomedical's SIR currently stands at 0.26. In other words for every 100,000 Clearside Biomedical shares traded daily on the market, roughly 260 shares are currently held short.
However Clearside Biomedical's short interest can also be evaluated against the total number of Clearside Biomedical shares, or, against the total number of tradable Clearside Biomedical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Clearside Biomedical's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Clearside Biomedical shares in existence, roughly 10 shares are currently held short) or 0.0086% of the tradable shares (for every 100,000 tradable Clearside Biomedical shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Clearside Biomedical.
Find out more about how you can short Clearside Biomedical stock.
We're not expecting Clearside Biomedical to pay a dividend over the next 12 months.
Over the last 12 months, Clearside Biomedical's shares have ranged in value from as little as $1.1 up to $4.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clearside Biomedical's is 1.4181. This would suggest that Clearside Biomedical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.